

Zelda Therapeutics Ltd
ACN 103 782 378
www.zeldatherapeutics.com

Level 45 108 St Georges Terrace, Perth Western Australia 6000

11 January 2017

## RELEASE FROM ESCROW

Zelda Therapeutics Ltd (ASX: ZLD, "Zelda" or the Company) advises that, pursuant with Listing Rule 3.10A that 500,000 fully paid ordinary shares will be released from escrow on 11 January 2017.

Zelda will apply for quotation of the escrowed shares upon their release from escrow in accordance with the ASX Listing Rules.

## **CONTACTS**

Corporate
Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors
Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Media
Andrew Ramadge
Media & Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (Aunt Zelda's) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols. Zelda will use this information to design a series of human clinical trials that have a high probability of success given the existing patient data and experiences it has access to.

In addition, Zelda has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry.